Literature DB >> 7738779

[Studies of novel 1,4-dihydropyridine Ca antagonist CS-905. I. Measurement of partition coefficient (log P) by high performance liquid chromatography (HPLC)].

K Masumoto1, A Takeyasu, K Oizumi, T Kobayashi.   

Abstract

A new 1,4-dihydropyridine derivative, CS-905, currently under development as a Ca antagonist, showed a gradual onset and long duration in its antihypertensive effect upon single oral administration. The partition coefficient for CS-905 was measured along with 11 known dihydropyridine Ca antagonists by the HPLC method to clarify its mode of action. The log PHPLC for CS-905 was, 5.18, almost the same as that of manidipine and this value is the highest among the measured drugs. Its pharmacokinetic profile in SHR was also discussed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7738779     DOI: 10.1248/yakushi1947.115.3_213

Source DB:  PubMed          Journal:  Yakugaku Zasshi        ISSN: 0031-6903            Impact factor:   0.302


  4 in total

1.  Potential prediction of formulation performance in paediatric patients using biopharmaceutical tools and simulation of clinically relevant administration scenarios of nifedipine and lorazepam.

Authors:  Anna C Van der Vossen; Lidwien M Hanff; Arnold G Vulto; Nikoletta Fotaki
Journal:  Br J Clin Pharmacol       Date:  2019-06-18       Impact factor: 4.335

2.  Major determinant factors of the extent of interaction between grapefruit juice and calcium channel antagonists.

Authors:  Ayako Ohnishi; Hisakazu Ohtani; Yasufumi Sawada
Journal:  Br J Clin Pharmacol       Date:  2006-08       Impact factor: 4.335

Review 3.  Manidipine: a review of its use in the management of hypertension.

Authors:  Kate McKeage; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

4.  Amlodipine attenuates oxidative stress in the heart and blood of high-cholesterol diet rabbits.

Authors:  I Salehi; M Mohammadi; F Mirzaei; F G Soufi
Journal:  Cardiovasc J Afr       Date:  2012-02       Impact factor: 1.167

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.